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Low-Gradient Aortic Stenosis
Need for an Integrated Approach, Including Assessment
of Symptoms, Hypertension, and Stenosis Severity*Philippe Pibarot, DVM, PHD, Marie-Annick Clavel, DVM, PHDSEE PAGE 55I n 2007, we reported that a substantial proportionof patients with severe aortic stenosis may havea low ﬂow (LF) (i.e., reduced stroke volume),
and thus, often have a low transvalvular pressure
gradient (LG), despite a preserved left ventricular
ejection fraction (LVEF) (1). The 2014 American Col-
lege of Cardiology (ACC)/American Heart Association
(AHA) guidelines (2) classiﬁed this “paradoxical”
LF/LG entity as a D3 stage of aortic stenosis, which
is deﬁned as an aortic valve area (AVA) of <1.0 cm2,
an indexed AVA of <0.6 cm2/m2, a mean gradient
of <40 mm Hg, a LVEF of >50%, and a stroke volume
index (SVi) of <35 ml/m2. Previous studies (3–13)
reported that patients with paradoxical LF/LG aortic
stenosis have worse outcomes than patients with
moderate aortic stenosis or with severe aortic steno-
sis and a high-gradient (HG) and that their outcomes
improve with aortic valve replacement (AVR).
Accordingly, the 2014 ACC/AHA guidelines included
a Class IIa (Level of Evidence: C) recommendation
for AVR in these patients: “AVR is reasonable in
symptomatic patients who have low-ﬂow, low-
gradient severe AS who are normotensive and have
a LVEF $50% if clinical, hemodynamic, and anatomic
data support valve obstruction as the most likely
cause of symptoms” (2). The main ﬁndings of the*Editorials published in the Journal of the American College of Cardiology
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paper to disclose.retrospective study by Tribouilloy et al. (14) pub-
lished in this issue of the Journal were: 1) patients
with LF/LG and preserved LVEF have similar out-
comes as patients with moderate aortic stenosis or
with severe aortic stenosis and a HG; and 2) AVR
does not improve these patients’ outcomes. The in-
vestigators should be commended for providing
important data on the challenging subset of patients
with paradoxical LF/LG aortic stenosis.OUTCOMES OF PATIENTS WITH
PARADOXICAL LF/LG
Because the gradient is a squared function of ﬂow, LF
is often associated with a LG, even with severe ste-
nosis. However, ﬂow and gradient are not synony-
mous and provide complementary information; ﬂow
is of prognostic importance as a marker for reduced
cardiac pump function and worse outcomes, whereas
gradient is of diagnostic importance because a LG with
a small AVA raises uncertainty about stenosis severity,
and thus, about the indication for AVR. Consequently,
several studies (8,15) and guidelines (2) recommend
classifying patients with small AVA and preserved
LVEF into 4 groups according to their levels of ﬂow
(i.e., SVi <35 or $35 ml/m2) and gradient (i.e., <40
or $40 mm Hg), each with different diagnostic, prog-
nostic, and therapeutic implications (Table 1): 1)
normal-ﬂow, low-gradient (NF/LG); 2) normal-ﬂow,
high-gradient (NF/HG); 3) LF/LG; and 4) low-ﬂow,
high-gradient (LF/HG).
The heart’s primary function is pumping blood
into the systemic circulation; thus, it appears logical
to measure its efﬁciency using the SVi, which is
TABLE 1 Outcome and Impact of Aortic Valve Replacement in Patients With Aortic Stenosis According to the Flow/Gradient Category
First Author, Year (Ref. #)
No. of
Patients
Mean Age,
yrs Endpoint
Mortality/Event Rates and Beneﬁt of AVR
Moderate AS
Low-Gradient AS High-Gradient AS Group With
The Highest
Mortality/
Event RateNF/LG LF/LG NF/HG LF/HG
Barasch et al., 2008 (3) Total: 215
HG: 168
LG: 47
77 2-yr mortality
2-yr mortality
— Medical: 19%
Post-AVR: 8.5%
Medical: 9.5%*
Post-AVR: 3%
LG
Pai et al., 2008 (4) LG: 52 76 5-yr mortality
5-yr mortality
AVR beneﬁt
— Medical: 80%
Post-AVR: 10%
AVR S[
— N/A
Belkin et al., 2011 (5) Total: 248
LG: 181
HG: 67
75 5-yr mortality
AVR beneﬁt
— 42%
AVR S[
45%
AVR S[
HG
Tarantini et al., 2011 (6) LG: 102 77 3.5-yr mortality
3.5-yr mortality
AVR beneﬁt
— Medical: 62%
Post-AVR: 26%
AVR S[
— N/A
Jander et al., 2011 (16) Total: 619
MAS: 184
LG: 435
68 4-yr CV mortality 4.9% 7.8% — — LG
Clavel et al., 2012 (7) Total: 561
MAS: 187
LF/LG: 187
NF/HG: 187
69 1-yr mortality
1-yr CV mortality
5-yr mortality
5-yr CV mortality
AVR beneﬁt
4%*
2%*
19%*
9%*
AVR NS
— 11%
9%
36%
26%
AVR S[
4%*
3%*
18%*
15%*
AVR S[
— LF/LG
Lancellotti et al., 2012 (8) Total: 150
NF/LG: 46
LF/LG: 11
NF/HG: 78
LF/HG: 15
70 2-yr cardiac event‡ — 17%† 73% 56%† 70%† LF/LG
Ozkan et al., 2013 (9) Total: 1,346
LG: 260
78 2.3-yr mortality
AVR beneﬁt
— Medical: 53%; Post-AVR:
26%
— N/A
AVR S[ AVR S[
Mehrotra et al., 2013 (10) Total: 113
MAS: 70
LF/LG: 38
NF/LG: 75
78 3-yr mortality 15%* 21%† 42% — — LF/LG
Eleid et al., 2013 (12) Total: 1,704
NF/LG: 352
LF/LG: 53
NF/HG: 1249
LF/HG: 50
77 2-yr mortality
2-yr mortality
AVR beneﬁt
— Overall: 15%†
Medical: 18%†
AVR NS
Overall: 40%
Medical: 56%
AVR S[
Overall: 18%†
Medical: 33%†
AVR S[
Overall: 22%†
Medical: 19%†
AVR NS
LF/LG
Mohty et al., 2013 (11) Total: 768
NF/LG: 172
LF/LG: 99
NF/HG: 386
LF/HG: 111
74 5-yr mortality
10-yr mortality
AVR beneﬁt
— 28%†
45%†
40%
68%
AVR S[
19%†
34%†
30%†
54%†
LF/LG
Maes et al., 2014 (17) Total: 349
LG: 205
HG: 144
78 4-yr mortality
4-yr mortality
AVR beneﬁt
— 52% 52% 68%† 71%† LF/HG
52%
AVR S[
69%*
AVR S[
Tribouilloy et al., 2014 (14) Total: 809
MAS: 420
LF/LG: 57
NF/LG: 85
HG: 247
77 2-yr mortality
2-yr mortality
4-yr mortality
4-yr mortality
AVR beneﬁt
Overall: 18%
Medical: 16%
Overall: 28%
Medical: 28%
AVR NS
Overall: 16%
Medical: 17%
Overall: 29%
Medical: 29%
AVR NS
Overall: 31%
Medical: 29%
Overall: 35%
Medical: 34%
AVR NS
Overall: 19%
Medical: 16%
Overall: 29%
Medical: 31%
AVR S[
LF/LG
*p # 0.05 from LG group. †p # 0.05 from LF/LG group. ‡Cardiac event: cardiovascular death or need for AVR motivated by the development of symptoms or left ventricular systolic
dysfunction.
AS ¼ aortic stenosis; AVR ¼ aortic valve replacement; AVR NS ¼ no signiﬁcant beneﬁt from AVR; AVR S[ ¼ signiﬁcant survival beneﬁt with AVR; CV ¼ cardiovascular; HG ¼ high-gradient;
LF ¼ low-ﬂow; LG ¼ low-gradient; MAS ¼ moderate aortic stenosis; N/A ¼ not applicable; NF ¼ normal-ﬂow.
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68routinely measured in echocardiographic or cathe-
terization laboratories for calculation of cardiac
output and AVA. As reported previously (1,3–8,10,11)
and corroborated by Tribouilloy et al. (14), 30% to
50% of aortic stenosis patients with preservedLVEF have LF (SVi <35 ml/m2). This is not necessarily
surprising, because the aortic stenosis population is
predominantly elderly, with frequent comorbidities
(e.g., hypertension, coronary artery disease, atrial
ﬁbrillation, pronounced LV concentric hypertrophy,
J A C C V O L . 6 5 , N O . 1 , 2 0 1 5 Pibarot and Clavel
J A N U A R Y 6 / 1 3 , 2 0 1 5 : 6 7 – 7 1 Need for an Integrated Approach
69mitral regurgitation, etc.) that may all contribute to
reduce SV. Accordingly, in the majority of previous
studies (1,3–8,10–13), patients with LF had worse
symptomatic status and prognosis. Moreover, com-
pared with patients with moderate aortic stenosis
and NF/LG or NF/HG aortic stenosis, those with
LF/LG generally have a higher risk of cardiac events,
all-cause mortality, and cardiovascular mortality
(Table 1).
However, a few studies (16,17), including the one
by Tribouilloy et al. (14), found similar prognoses
for patients with LF/LG and those with moderate,
NF/LG, or NF/HG aortic stenosis (Table 1). These
discrepancies among studies underline the point
that LF/LG aortic stenosis is a heterogeneous subset
that includes patients with measurement errors,
patients with small body size, and patients with
bona ﬁde paradoxical LF/LG. In the SEAS (Simva-
statin and Ezetimibe in Aortic Stenosis) (16), which
included only asymptomatic patients with mild-
to-moderate aortic stenosis, 70% of patients had LF
(vs. <50% in other studies), which suggested a SVi
underestimation and LF overestimation in a signiﬁ-
cant proportion of patients. In the study by Tri-
bouilloy et al. (14), the proportions of LF and LF/LG
were similar to previous studies (1,3–13). However,
a single group (HG aortic stenosis) included NF/HG
and LF/HG patients, making the impact of LF versus
LG on outcomes difﬁcult to delineate. In univariable
analysis, mortality at 2 years was 2-fold higher in the
LF/LG group than in the other 3 groups (Table 1),
although this was not statistically signiﬁcant. This
was likely related to the lack of statistical power,
because the LF/LG group had only 57 patients with
approximately 15 deaths. After adjustment for mul-
tiple variables, including several causative factors of
LF (e.g., age, atrial ﬁbrillation, coronary artery dis-
ease), patients with LF/LG had outcomes similar to
those with moderate aortic stenosis or NF/LG, and
better outcomes than those with HG aortic stenosis.
Because individual patients cannot be adjusted for
age and other comorbidities, the multivariable mo-
dels are less clinically relevant than the univariable
analysis [Figure 1 of the Tribouilloy et al. paper (14)],
which better reﬂects the patient’s actual risk. These
results clearly support LF/LG as a marker for in-
creased risk of midterm mortality, as also shown in
other studies (1,3–13).
Although Tribouilloy et al. did not report body
mass index and obesity data (14), other baseline
characteristics (i.e., 35% of patients with type-2
diabetes) suggest that obesity might have been more
prevalent in the LF/LG aortic stenosis group. Obesity
may lead to underestimation of SVi, and thus tomisclassiﬁcation of patients with NF into the LF
group. Moreover, several studies reported an obesity
paradox: a protective effect of a larger body mass
index in the elderly population with aortic stenosis.
Hence, obesity may have an important confounding
effect, leading to underestimation of the impact of
LF on outcomes.
The similar prognoses observed after multivariable
adjustment in the LF/LG group versus the moderate
aortic stenosis group (14) may result from a signiﬁ-
cant proportion of the patients with LF/LG having
nonsevere stenosis. With low transvalvular ﬂow, the
forces applied against the valve cusps may not
be sufﬁcient to completely open an only mildly or
moderately stenotic valve. In previous studies, 30%
to 40% of patients with paradoxical LF/LG aortic
stenosis had pseudosevere aortic stenosis (18–20).
Hence, other diagnostic methods, such as low-dose
dobutamine stress echocardiography or aortic valve
calcium scoring by multidetector computed tomog-
raphy (MDCT), are essential to conﬁrm stenosis
severity and rule out pseudosevere stenosis in pa-
tients with LF/LG with preserved LVEF. In the
study by Tribouilloy et al. (14) (as in most previous
studies), no systematic investigation conﬁrmed ste-
nosis severity in patients with LF/LG or NF/LG
aortic stenosis.
IMPACT OF AVR ON OUTCOMES OF PATIENTS
WITH PARADOXICAL LF/LG
Does AVR improve outcomes in patients with LF/LG
aortic stenosis? The majority of studies have shown
that AVR is associated with signiﬁcant survival
beneﬁt in these patients (Table 1) (4–7,9,11–13,17),
whereas Tribouilloy et al. (14) reported no beneﬁt.
However, very few (<10) patients in the LF/LG
group underwent AVR, and with such limited sta-
tistical power, it is difﬁcult to draw a deﬁnitive
conclusion. In addition, 61% of the HG severe aortic
stenosis group were symptomatic at baseline, and
thus, had a class I indication for AVR (14).
Furthermore, a large proportion of patients who
were asymptomatic at baseline likely became
symptomatic during follow-up, thus presenting an
indication for AVR. However, only 53% of patients
in the HG aortic stenosis group underwent AVR
during follow-up. Underutilization of AVR in these
symptomatic patients with severe aortic stenosis
could result from the inclusion in the study of
relatively old patients with several cardiovascular
(and probably noncardiovascular) comorbidities.
This could also explain the worse outcomes in the
HG group.
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70The main limitation of most of the previously pub-
lished studies was that they were nonrandomized,
often retrospective, or ambispective. The only study
comparing AVR versus conservative management in
patients with paradoxical LF/LG aortic stenosis that
used a randomized design was the post-hoc analysis
of the PARTNER-I (Placement of Aortic Transcatheter
Valve Trial) (21). In PARTNER-I, cohort B (inoperable
patients), compared with conservative management,
transcatheter AVR was associated with a major sur-
vival beneﬁt in patients with LF/LG aortic stenosis and
preserved LVEF. Moreover, in cohort A (patients at
high operative risk), compared with surgical AVR,
transcatheter AVR was associated with signiﬁcantly
better survival during the ﬁrst year of follow-up.
Further studies are needed to determine which pa-
tients with paradoxical LF/LG aortic stenosis would
beneﬁt from AVR and which type of AVR (surgical vs.
transcatheter) should be used.
MANAGEMENT OF PATIENTS WITH
PARADOXICAL LF/LG
When confronted with a patient with a small AVA
(<1.0 cm2), small indexed AVA (<0.6 cm2/m2), a low
gradient (<40 mm Hg), a preserved LVEF ($50%), and
a low SVi (<35 ml/m2), one should ﬁrst rule out
measurement errors and conﬁrm that this is bona ﬁde
paradoxical LF/LG aortic stenosis, and not moderate
aortic stenosis with an underestimated SVi and AVA
or severe aortic stenosis with an underestimated
gradient. The 2014 ACC/AHA guidelines (2) recom-
mend consideration of AVR (Class IIa) in patients with
LF/LG and preserved LVEF if they are symptomatic,
normotensive, and have evidence of severe stenosis.
The following algorithm for clinical decision-making
addresses these key criteria.
STEP 1: IS THE PATIENT SYMPTOMATIC? If asymp-
tomatic (conﬁrmed by exercise testing), the patient
can likely be managed conservatively. In Tribouilloy
et al. (14), 44% of LF/LG patients were asymptom-
atic. If symptomatic, proceed to the second step.
STEP 2: IS THE PATIENT HYPERTENSIVE? If so,
antihypertensive therapy should be initiated or opti-
mized, and symptoms and echocardiographic pa-
rameters should be reassessed after normalization of
blood pressure. In Tribouilloy et al. (14), 77% of the
LF/LG group had a history of hypertension, and>50% had inadequately controlled blood pressure
(systolic pressure >140 mm Hg). Hypertension may
lead to decreased ﬂow, and thus, to a decreased
gradient, and may contribute to symptoms and ad-
verse events. If the LF/LG pattern and symptoms
persist after optimization of antihypertensive ther-
apy, proceed to the third step.
STEP 3: IS THE STENOSIS SEVERE? Pseudosevere
aortic stenosis, which may be present in 30% to 40% of
LF/LG aortic stenosis patients (18–20), must be ruled
out. Low-dose dobutamine stress echocardiography
may be used (18), but may not be applicable and/or
conclusive in a signiﬁcant proportion of patients with
paradoxical LF/LG aortic stenosis, particularly in those
with restrictive LV physiology. Alternatively, true-
severe versus pseudosevere aortic stenosis may be
differentiated using quantiﬁcation of aortic valve
calciﬁcation by MDCT, by applying different cutpoints
inwomen (>1,200 AU) versusmen (>2,000 AU) (19,20).
The guidelines (2) do not address the situation of
patients with small AVA and NF/LG. Several studies
(8,10–13) reported better outcomes in these patients
than in those with LF/LG or with HG, and that AVR
generally did not improve their outcomes (Table 1).
However, recent studies (19) suggested that a signif-
icant proportion of these patients might have hemo-
dynamically severe stenosis. Hence, an approach
including optimization of antihypertensive therapy
and conﬁrmation of stenosis severity with additional
diagnostic tests should probably be considered in a
symptomatic patient with NF/LG.
CONCLUSIONS
Paradoxical LF/LG aortic stenosis is a challenging,
heterogeneous clinical entity that requires special
attention and further studies. Collectively, published
studies (Table 1) support the guidelines’ recommen-
dation (2) that AVR is reasonable in symptomatic and
normotensive patients with paradoxical LF/LG if
the stenosis is truly severe and the likely cause of
symptoms.
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